Tyers Asset Management LLC Purchases 1,840 Shares of Charles River Laboratories Intl. Inc (NYSE:CRL)

Tyers Asset Management LLC boosted its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 28.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,336 shares of the medical research company’s stock after buying an additional 1,840 shares during the quarter. Tyers Asset Management LLC’s holdings in Charles River Laboratories Intl. were worth $1,183,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. NEXT Financial Group Inc raised its holdings in Charles River Laboratories Intl. by 4.7% in the second quarter. NEXT Financial Group Inc now owns 2,019 shares of the medical research company’s stock worth $286,000 after buying an additional 90 shares during the last quarter. State Treasurer State of Michigan boosted its position in shares of Charles River Laboratories Intl. by 0.6% during the first quarter. State Treasurer State of Michigan now owns 17,200 shares of the medical research company’s stock worth $2,498,000 after acquiring an additional 100 shares during the last quarter. Mountain Pacific Investment Advisers Inc. ID increased its holdings in Charles River Laboratories Intl. by 1.7% in the 1st quarter. Mountain Pacific Investment Advisers Inc. ID now owns 7,298 shares of the medical research company’s stock valued at $1,060,000 after acquiring an additional 120 shares during the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of Charles River Laboratories Intl. by 5.4% during the 2nd quarter. Zions Bancorporation N.A. now owns 2,421 shares of the medical research company’s stock valued at $344,000 after purchasing an additional 124 shares during the last quarter. Finally, Bbva USA Bancshares Inc. boosted its stake in Charles River Laboratories Intl. by 2.6% during the second quarter. Bbva USA Bancshares Inc. now owns 5,692 shares of the medical research company’s stock valued at $808,000 after buying an additional 146 shares during the last quarter. 94.40% of the stock is owned by institutional investors and hedge funds.

In related news, insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $130.36, for a total value of $162,819.64. Following the completion of the sale, the insider now directly owns 19,327 shares of the company’s stock, valued at $2,519,467.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.80% of the stock is owned by corporate insiders.

NYSE CRL traded up $0.65 on Wednesday, reaching $130.33. 125,793 shares of the stock traded hands, compared to its average volume of 233,653. Charles River Laboratories Intl. Inc has a 12 month low of $103.00 and a 12 month high of $149.07. The company has a market cap of $6.35 billion, a price-to-earnings ratio of 21.61, a PEG ratio of 1.66 and a beta of 1.09. The company has a fifty day moving average price of $132.09 and a 200-day moving average price of $136.35. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.08. The business had revenue of $657.60 million for the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.62 EPS. As a group, research analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on the stock. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Leerink Swann began coverage on shares of Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating for the company. Zacks Investment Research downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Svb Leerink started coverage on Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating and a $155.00 target price for the company. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $147.62.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: How does new data get added to a blockchain?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.